Expected Moves

High probability of an equity or structured debt offering to address working capital deficits following Q2 results. Modeled from a $0.03 base price, the scenario projects a highly dilutive fallback to $0.02, with a $0.04 target on a favorable structure.

Potential timeline for a B2B digital health partnership announcement to validate their core machine learning platform. Analyzing from a $0.01 base price, with a target of $0.03 and a terminal fallback of $0.01.

Expected Q3 2026 financial results detailing whether AI commercialization efforts are translating to top-line growth. Evaluated from a depressed $0.02 base price, the upside target sits at $0.03 against a $0.01 fallback.

Full-year fiscal 2026 reporting, carrying the heavy risk of an auditor going-concern qualification due to cumulative losses. Anchored at a $0.03 base price, the upside target is $0.04 while the fallback sits at $0.02.